November 28 2007

VeriChip Corporation to Unveil Plans for Self-Contained Implantable RFID Glucose-Sensing Microchip at Grand Hyatt in New York on December 4

Dr. Manny Alvarez to speak at event

DELRAY BEACH, Fla – November 28, 2007 - VeriChip Corporation ("VeriChip") (NASDAQ: CHIP), a provider of RFID systems for healthcare and patient-related needs, and its project partners Digital Angel Corporation ("Digital Angel") (AMEX: DOC) and Receptors LLC announced today they will host an event for the medical,  diabetic and investment communities on December 4th in New York to unveil details, including plans to build a prototype self-contained implantable bio-sensing device included in an RFID microchip (the “Microchip”)  that for the first time will have the ability to measure glucose levels in the human body. Millions of patients with diabetes utilize needle sticks to monitor levels of glucose on a daily basis. Through the Microchip, patients are expected to be able to track glucose levels without the constant invasive and painful effect of a needle. Prior to the event, the Company will issue a “white paper” describing the features, benefits and technology underlying the development of its revolutionary self-contained implantable glucose-sensing device.

The event will take place at the Grand Hyatt at 4:30 p.m. EST and feature a presentation by Robert E. Carlson, Ph.D., President and Principal Investigator at RECEPTORS LLC, which is an expert in the field of proteomics and the development of artificial receptors. RECEPTORS has partnered with VeriChip and Digital Angel to develop an innovative self-contained glucose-sensing system.

According to the Centers for Disease Control and Prevention (CDC), as of 2005 diabetes affects nearly 21 million Americans – or 7 percent of the U.S. population, including an additional 2.6 million people with diabetes since 2002. Another 41 million people are estimated to have pre-diabetes, a condition that increases the risk of developing type 2 diabetes – the most common form of the disease – as well as heart disease and stroke.

Dr. Manny Alvarez, Chairman of the Department of Obstetrics and Gynecology and Reproductive Science at Hackensack University Medical Center and FoxNews.com health managing editor, will speak at the event.

Commenting on the event, Scott R Silverman, Chairman and CEO of VeriChip Corporation stated “Upon complete development, this technology can change the lives of patients with diabetes, providing them with a convenient way to monitor their blood-sugar levels. Today, the common method involves a prick of the finger. Our self-contained sensor can change that and negate the need for daily invasive testing. This system will allow for one injection every 4-6 months (approximate) that permits the diabetic to externally scan the device and retrieve a blood sugar reading as often as necessary.”

Parties interested in attending the New York event should contact Allison Tomek at (561) 805-8008 as soon as possible. Space is limited and registration will be accepted on a first-come, first-served basis.

About RECEPTORS LLC

RECEPTORS' technology originates from its CARA (TM) AFFINITY BY DESIGN(TM) Discovery Platform, which allows the company to optimize artificial receptors to any application. Its product suite focuses on the development of an integrated proteomics "toolkit", with an emphasis on high-performance protein isolation and biomarker discovery. RECEPTORS LLC is privately held. For more information on RECEPTORS, please call 1-952-448-4337, or email info@receptorsllc.com. Additional information can be found online at http://www.receptorsllc.com.

About VeriChip

VeriChip, headquartered in Delray Beach, Florida, develops, markets and sells radio frequency identification, or RFID, systems used to identify, locate and protect people and assets. VeriChip's goal is to become the leading provider of RFID systems for people in the healthcare industry. The Company recently began marketing its VeriMed(TM) Patient Identification System, a passive RFID system for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, the implantable VeriChip(TM), cleared for medical use in October 2004 by the United States Food and Drug Administration.

VeriChip Corporation is majority-owned by Applied Digital Solutions, Inc. (NASDAQ: ADSX), which also owns a majority position in Digital Angel Corporation (AMEX: DOC). Digital Angel, a leader in RFID and GPS technologies, owns the patent on the human implantable, passive RFID microchip and manufactures it for VeriChip. For more information on VeriChip, please call 1-800-970-2447, or email info@verichipcorp.com. Additional information can be found online at www.verichipcorp.com.

About Digital Angel Corporation

Digital Angel Corporation (AMEX:DOC) is a leading provider of radio frequency identification (RFID) and global positioning system (GPS) technologies that enable the rapid and accurate identification, location tracking and condition monitoring of people, animals and high-value assets.  The company’s products are utilized around the world in such applications as pet identification using its patented, FDA-approved implantable microchip; livestock identification and tracking using visual and RFID ear tags; and GPS search and rescue beacons for use on aircraft, ships and boats, and by adventure enthusiasts. Digital Angel Corporation has entered into an agreement to merge with its parent company Applied Digital Solutions, Inc. (NASDAQ:ADSX).

This press release includes forward-looking statements, including but not limited to statements regarding the potential development, clinical trials and commercialization of an implantable glucose-sensing microchip, the potential of the microchip to revolutionize diabetes care and management and to negate the need for diabetics to draw blood to monitor blood glucose levels, its ability to painlessly and accurately scan, determine, and transmit glucose concentration levels to a wireless scanner, and the potential for it to operate properly within the human body for the timeframe intended. VeriChip and Digital Angel wish to caution readers that certain important factors and various risks may have affected and could in the future affect VeriChip's and Digital Angel's actual results and could cause VeriChip's and Digital Angel's actual results for subsequent periods to differ materially from those expressed in any forward-looking statement made by or on behalf of VeriChip and Digital Angel. With respect to VeriChip's and Digital Angel's expectations expressed in this press release, such risk factors include, but are not limited to, the performance of the product according to VeriChip's and Digital Angel's expectations. This information is also qualified in its entirety by cautionary statements and risk factor disclosures contained in VeriChip's and Digital Angel's Securities and Exchange Commission filings, including VeriChip's and Digital Angel's annual reports on Form 10-K for the fiscal year ended December 31, 2006 and its quarterly reports. VeriChip and Digital Angel can offer no assurances that any projections, assumptions or forecasts made or discussed in this release will be met, and investors should understand the risks of investing solely due to such projections. VeriChip and Digital Angel undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

Contacts:

VeriChip and Digital Angel

Allison Tomek, 561-805-8008

or

CEOcast

Dan Schustack, 212-732-4300

or

RECEPTORS LLC

Kris Vanella, 952-448-4337